| Drug General Information |
| Drug ID |
D0X8TP
|
| Former ID |
DNC001384
|
| Drug Name |
SU10991
|
| Drug Type |
Small molecular drug
|
| Indication |
Multiple myeloma [ICD9: 203; ICD10:C90]
|
Investigative |
[1]
|
|---|
| Company |
Sugen Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H15N5
|
| Canonical SMILES |
CCN(CC)C1=CC(=NC2=NC=NN12)C
|
| InChI |
1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
|
| InChIKey |
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
866458, 5659229, 7848283, 8153404, 11112623, 11467040, 11468160, 11486770, 14745540, 14748788, 29224573, 47810921, 47959939, 48110614, 48259417, 49699027, 50057667, 50086436, 50100500, 56365869, 57322829, 74813390, 85787550, 88858725, 92126029, 92133451, 93815048, 103371622, 103914683, 104309497, 105640614, 117431105, 121363700, 124799773, 125432948, 126922620, 127999928, 134340574, 134340639, 134991679, 137248780, 144204129, 162249201, 162796478, 169428974, 170465770, 175612102, 178126772, 179149421, 184547380
|
| SuperDrug ATC ID |
C01DX11
|
| SuperDrug CAS ID |
cas=015421848
|
| Target and Pathway |
| Target(s) |
FGF-3 receptor |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancer
|
|
Central carbon metabolism in cancer
|
|
PANTHER Pathway
|
FGF signaling pathway
|
|
Reactome
|
FGFR3 mutant receptor activation
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Bladder Cancer
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
| References |
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. |
|---|
